Literature DB >> 28223385

Deletion of nudB Causes Increased Susceptibility to Antifolates in Escherichia coli and Salmonella enterica.

Kun Li1, Ting Li1, Shan-Shan Yang1, Xu-De Wang1, Lei-Xin Gao1, Rui-Qi Wang1, Jing Gu1, Xian-En Zhang2, Jiao-Yu Deng3.   

Abstract

Co-trimoxazole, a fixed-dose combination of sulfamethoxazole (SMX) and trimethoprim (TMP), has been used for the treatment of bacterial infections since the 1960s. Since it has long been assumed that the synergistic effects between SMX and TMP are the consequence of targeting 2 different enzymes of bacterial folate biosynthesis, 2 genes (pabB and nudB) involved in the folate biosynthesis of Escherichia coli were deleted, and their effects on the susceptibility to antifolates were tested. The results showed that the deletion of nudB resulted in a lag of growth in minimal medium and increased susceptibility to both SMX and TMP. Moreover, deletion of nudB also greatly enhanced the bactericidal effect of TMP. To elucidate the mechanism of how the deletion of nudB affects the bacterial growth and susceptibility to antifolates, 7,8-dihydroneopterin and 7,8-dihydropteroate were supplemented into the growth medium. Although those metabolites could restore bacterial growth, they had no effect on susceptibilities to the antifolates. Reverse mutants of the nudB deletion strain were isolated to further study the mechanism of how the deletion of nudB affects susceptibility to antifolates. Targeted sequencing and subsequent genetic studies revealed that the disruption of the tetrahydromonapterin biosynthesis pathway could reverse the phenotype caused by the nudB deletion. Meanwhile, overexpression of folM could also lead to increased susceptibility to both SMX and TMP. These data suggested that the deletion of nudB resulted in the excess production of tetrahydromonapterin, which then caused the increased susceptibility to antifolates. In addition, we found that the deletion of nudB also resulted in increased susceptibility to both SMX and TMP in Salmonella enterica Since dihydroneopterin triphosphate hydrolase is an important component of bacterial folate biosynthesis and the tetrahydromonapterin biosynthesis pathway also exists in a variety of bacteria, it will be interesting to design new compounds targeting dihydroneopterin triphosphate hydrolase, which may inhibit bacterial growth and simultaneously potentiate the antimicrobial activities of antifolates targeting other components of folate biosynthesis.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  nudB; sulfamethoxazole; susceptibility; tetrahydromonapterin; trimethoprim

Mesh:

Substances:

Year:  2017        PMID: 28223385      PMCID: PMC5404538          DOI: 10.1128/AAC.02378-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  20 in total

Review 1.  International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases.

Authors:  Kalpana Gupta; Thomas M Hooton; Kurt G Naber; Björn Wullt; Richard Colgan; Loren G Miller; Gregory J Moran; Lindsay E Nicolle; Raul Raz; Anthony J Schaeffer; David E Soper
Journal:  Clin Infect Dis       Date:  2011-03-01       Impact factor: 9.079

Review 2.  Trimethoprim and sulfonamide resistance.

Authors:  P Huovinen; L Sundström; G Swedberg; O Sköld
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

3.  A randomized, double-blind study of the efficacy of fleroxacin versus trimethoprim-sulfamethoxazole in men with culture-proven chancroid.

Authors:  P J Plourde; L J D'Costa; E Agoki; J Ombette; J O Ndinya-Achola; L A Slaney; A R Ronald; F A Plummer
Journal:  J Infect Dis       Date:  1992-05       Impact factor: 5.226

4.  Trimethoprim: laboratory and clinical studies.

Authors:  J H Darrell; L P Garrod; P M Waterworth
Journal:  J Clin Pathol       Date:  1968-03       Impact factor: 3.411

5.  Low-dose trimethoprim-sulfamethoxazole prophylaxis for toxoplasmic encephalitis in patients with AIDS.

Authors:  A Carr; B Tindall; B J Brew; D J Marriott; J L Harkness; R Penny; D A Cooper
Journal:  Ann Intern Med       Date:  1992-07-15       Impact factor: 25.391

6.  Co-trimoxazole prophylaxis is associated with reduced risk of incident tuberculosis in participants in the Swiss HIV Cohort Study.

Authors:  Barbara Hasse; A Sarah Walker; Jan Fehr; Hansjakob Furrer; Matthias Hoffmann; Manuel Battegay; Alexandra Calmy; Jacques Fellay; Caroline Di Benedetto; Rainer Weber; Bruno Ledergerber
Journal:  Antimicrob Agents Chemother       Date:  2014-02-10       Impact factor: 5.191

7.  Clinical manifestations and therapy of Isospora belli infection in patients with the acquired immunodeficiency syndrome.

Authors:  J A DeHovitz; J W Pape; M Boncy; W D Johnson
Journal:  N Engl J Med       Date:  1986-07-10       Impact factor: 91.245

8.  Escherichia coli orf17 codes for a nucleoside triphosphate pyrophosphohydrolase member of the MutT family of proteins. Cloning, purification, and characterization of the enzyme.

Authors:  S F O'Handley; D N Frick; L C Bullions; A S Mildvan; M J Bessman
Journal:  J Biol Chem       Date:  1996-10-04       Impact factor: 5.157

9.  A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. The Dutch AIDS Treatment Group.

Authors:  M M Schneider; A I Hoepelman; J K Eeftinck Schattenkerk; T L Nielsen; Y van der Graaf; J P Frissen; I M van der Ende; A F Kolsters; J C Borleffs
Journal:  N Engl J Med       Date:  1992-12-24       Impact factor: 91.245

10.  Single-blind comparative trial of trimethoprim-sulphamethoxazole and ampicillin in the treatment of exacerbations of chronic bronchitis.

Authors:  D T Hughes
Journal:  Br Med J       Date:  1969-11-22
View more
  4 in total

1.  Effects of cotrimoxazole prophylaxis on Talaromyces marneffei infection in HIV/AIDS patients receiving antiretroviral therapy: a retrospective cohort study.

Authors:  Junjun Jiang; Fengxiang Qin; Sirun Meng; Eric J Nehl; Jinping Huang; Yanfen Liu; Jun Zou; Wenyi Dong; Jiegang Huang; Hui Chen; Ning Zang; Bingyu Liang; Chuanyi Ning; Yanyan Liao; Chaolian Luo; Huifang Liu; Xin Liu; Jian Wang; Oulu Zhou; Thuy Le; Li Ye; Fengyao Wu; Hao Liang
Journal:  Emerg Microbes Infect       Date:  2019       Impact factor: 7.163

2.  Characterization of pncA Mutations and Prediction of PZA Resistance in Mycobacterium tuberculosis Clinical Isolates From Chongqing, China.

Authors:  Kun Li; Zhongping Yang; Jing Gu; Ming Luo; Jiaoyu Deng; Yaokai Chen
Journal:  Front Microbiol       Date:  2021-01-11       Impact factor: 5.640

3.  Mutations of folC cause increased susceptibility to sulfamethoxazole in Mycobacterium tuberculosis.

Authors:  Ruiqi Wang; Kun Li; Jifang Yu; Jiaoyu Deng; Yaokai Chen
Journal:  Sci Rep       Date:  2021-01-14       Impact factor: 4.379

4.  Methionine Antagonizes para-Aminosalicylic Acid Activity via Affecting Folate Precursor Biosynthesis in Mycobacterium tuberculosis.

Authors:  Michael D Howe; Shannon L Kordus; Malcolm S Cole; Allison A Bauman; Courtney C Aldrich; Anthony D Baughn; Yusuke Minato
Journal:  Front Cell Infect Microbiol       Date:  2018-11-12       Impact factor: 5.293

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.